

1 **Auditory Complications among Childhood Cancer Survivors and Health-** 2 **related Quality of Life: A PanCareLIFE study**

3 Sven Strebel^{1,2,3*}, Katja Baust^{4*}, Desiree Grabow⁵, Julianne Byrne⁶, Thorsten Langer⁷,
4 Antoinette am Zehnhoff-Dinnesen⁸, Rahel Kuonen^{1,9}, Annette Weiss^{1,10}, Tomas Kepak¹¹,
5 Jarmila Kruseova¹², Claire Berger^{13,14}, Gabriele Calaminus⁴,
6 Grit Sommer^{1,15,16*}, Claudia E. Kuehni^{1,17*✉}, and on behalf of the PanCareLIFE Consortium

7 ¹ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

8 ² CANSEARCH research platform in pediatric oncology and hematology, Department of Pediatrics, Gynecology
9 and Obstetrics, University of Geneva, Geneva, Switzerland

10 ³ Graduate School for Health Sciences, University of Bern, Bern, Switzerland

11 ⁴ Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany

12 ⁵ Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical
13 Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg
14 University Mainz, Mainz, Germany

15 ⁶ Boyne Research Institute, Drogheda, Ireland

16 ⁷ Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck,
17 Germany

18 ⁸ Department for Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelms University,
19 Münster, Germany

20 ⁹ Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

21 ¹⁰ Bavarian Care and Nursing Authority, Amberg, Germany

22 ¹¹ University Hospital Brno & International Clinical Research Center (FNUSA-ICRC), Masaryk University,
23 Brno, Czech Republic

24 ¹² Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and
25 University Hospital Motol, Prague, Czech Republic

26 ¹³ Department of Pediatric Hematology and Oncology, University-Hospital, Saint-Étienne, France

27 ¹⁴ Lyon University, Jean Monnet University, INSERM, U 1059, Sainbiose, Saint-Étienne, France

28 ¹⁵ Department of Pediatric Endocrinology, Diabetology and Metabolism, Inselspital, Bern University Children's
29 Hospital, University of Bern, Bern, Switzerland

30 ¹⁶ Department of BioMedical Research, University of Bern, Bern, Switzerland

31 ¹⁷ Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital,
32 University of Bern, Bern, Switzerland

33 *these authors contributed equally; ✉Corresponding author

34 Correspondence to: Claudia E. Kuehni, Prof. MD; Institute of Social and Preventive
35 Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland; E-mail:
36 claudia.kuehni@ispm.unibe.ch; Telephone: +41 31 684 35 07

37 **Key words:** childhood cancer; survivorship; quality of life; hearing loss;
38 Tinnitus

39 Abbreviations

BMI	Body Mass Index
BP	Bodily pain
CCS	Childhood cancer survivors
CCSS	American Childhood Cancer Survivor Study
CH	Switzerland
CI	95% Confidence interval
CNS	Central nervous system
Coef.	Estimated beta coefficient from linear regression
CRT	Cranial radiation therapy
CZ	The Czech Republic
DE	Germany
FR	France
GH	General health
HRQoL	Health-related quality of life
HSCT	hematopoietic stem cell transplantation
ICCC-3	International Classification of Childhood Cancer, Third edition
IQR	Interquartile range
MCS	Mental component summary
MH	Mental health
PCL	PanCareLIFE
PCS	Physical component summary
PF	Physical functioning
RE	Role emotional
RP	Role physical
SCCSS	Swiss Childhood Cancer Survivor Study
SF	Social functioning
SF-36	Short-Form 36 questionnaire
VT	Vitality

40 ABSTRACT

41 Auditory complications are potential side effects from childhood cancer treatment. Yet,
42 limited evidence exists about the impact of auditory complications—particularly tinnitus—on
43 health-related quality of life (HRQoL) among childhood cancer survivors (CCS). We
44 determined the prevalence of hearing loss and tinnitus in the large European PanCareLIFE
45 cohort of CCS and examined its effect on HRQoL. We included CCS from four European
46 countries who were diagnosed at age ≤ 18 years; survived ≥ 5 years; and aged 25–44 years at
47 study. We assessed HRQoL (Short Form 36), hearing loss, and tinnitus using questionnaires.
48 We used multivariable linear regression to examine associations between these two auditory
49 complications and HRQoL adjusting for socio-demographic and clinical factors. Our study
50 population consisted of 6,318 CCS (53% female; median age at cancer diagnosis 9 years
51 interquartile range [IQR] 5–13 years) with median age at survey of 31 years (IQR 28–35
52 years). Prevalence was 7.5% (confidence interval [CI]: 6.9–8.2) for hearing loss and 7.6%
53 (CI: 6.4–9.0) for tinnitus. CCS with hearing loss had impaired physical (coefficient [coef.] -
54 4.3, CI: -7.0 to -1.6) and mental (coef. -3.2, CI: -5.5 to -0.8) HRQoL when compared with
55 CCS with normal hearing. Tinnitus was also associated with impaired physical (coef. -8.2, CI:
56 -11.8 to -4.7) and mental (coef. -5.9, CI: -8.8 to -3.1) HRQoL. We observed the lowest
57 HRQoL among CCS with both hearing loss and tinnitus. Our findings indicate timely
58 treatment of hearing loss and tinnitus may contribute to quality of life of survivors.

59 INTRODUCTION

60 Cancer treatment can cause auditory complications, such as hearing loss and tinnitus.^{1,2} In
61 recent surveys, childhood cancer survivors (CCS) reported more hearing loss and tinnitus
62 when compared with their siblings.^{3,4} Ototoxic cancer treatments include platinum-based
63 chemotherapy, cranial radiotherapy (CRT), and surgeries involving the auditory system.^{1,4,5}
64 Other suspected ototoxic treatments are concomitant medications such as aminoglycosides or
65 loop diuretics, hematopoietic stem cell transplantation (HSCT), or the neurotoxic vinca
66 alkaloid vincristine.⁵⁻⁷ Hearing loss and tinnitus lead to a wide range of educational and
67 psychosocial problems such as learning difficulties and emotional distress among CCS and
68 the general population.⁸⁻¹¹ The overall burden of auditory complications ultimately affects
69 health-related quality of life (HRQoL) of CCS.¹²⁻¹⁴

70 Only a few studies have investigated auditory complications and how they affect HRQoL
71 among CCS.¹²⁻¹⁴ Previous studies with small sample sizes and heterogeneous inclusion
72 criteria make comparisons between studies difficult since findings can only be extrapolated to
73 the overall CCS population to a limited extent. The association of tinnitus with HRQoL
74 among CCS remains unknown. Several studies examined the prevalence of hearing loss
75 among CCS treated with cisplatin or CRT, yet studies of the overall population—and studies
76 investigating tinnitus—are scarce.^{3,4,15,16} We thus combined harmonized data from four
77 European countries into a large cohort of CCS to describe the prevalence of hearing loss and
78 tinnitus and investigate their association with HRQoL.

79 **METHODS**

80 **Study population**

81 PanCareLIFE (PCL) is a European-based study on late effects among CCS. It focuses on
82 hearing loss, fertility problems, and quality of life.^{17, 18} For the current study, we included
83 CCS from Switzerland (CH), Czech Republic (CZ), Germany (DE), and France (FR). The
84 study population included national or regional cohorts of CCS 1) diagnosed with cancer
85 according to the International Classification of Childhood Cancer (ICCC-3), 3rd edition,¹⁹ or
86 Langerhans cell histiocytosis; 2) aged ≤ 18 years at time of cancer diagnosis; 3) survived ≥ 5
87 years after cancer diagnosis; 4) were off treatment for cancer at time of study; 5) aged 25-44
88 years when they received the questionnaire. To make data comparable between countries, we
89 restricted our analysis to CCS ≥ 25 years and < 45 years because data for CCS younger than 25
90 years were unavailable for the German cohort and data for CCS older than 45 years were
91 unavailable for the French cohort. Details about study design, recruitment of participants,
92 country-specific exclusion criteria, and characteristics of different cohorts were published in a
93 separate study protocol.¹⁷

94 **Study procedure**

95 Each country sent questionnaires to their respective regional or national cohorts between
96 2005 and 2017.¹⁷ The questionnaires were sent by mail except in CZ where clinic staff
97 distributed them during follow-up visits to former patients. The questionnaire included
98 questions about HRQoL, hearing, socio-demographic characteristics, and lifestyle behavior.
99 Non-responders were reminded to complete the questionnaire.¹⁷ Clinical information on

100 cancer diagnosis and treatment was extracted from medical records by each participating
101 country.

102 **Assessment of HRQoL**

103 We assessed HRQoL with the Short-Form 36 (SF-36) questionnaire.²⁰ The SF-36 is a
104 widely used instrument; several studies used it to determine HRQoL among CCS.^{12, 21-24} The
105 questionnaire includes 36 items covering different aspects of physical and mental health
106 aggregated into eight health domains: physical functioning (PF, 10 items), role-limitations due
107 to physical problems (RP, 4 items), bodily pain (BP, 2 items), general health (GH, 5 items),
108 vitality (VT, 4 items), social functioning (SF, 2 items), role-limitations due to emotional
109 problems (RE, 3 items) and mental health (MH, 5 items).^{20, 25} These health domains are
110 further collapsed into summary scores that reflect overall physical and mental health: physical
111 component summary (PCS) and mental component summary (MCS). We converted all raw
112 scores into T-scores ranging from 0–100 for each health domain. A higher score indicates
113 better HRQoL. The T-scores were further transformed according to reference data from the
114 German norm population stratified for age and sex (mean=50, SD=10).^{17, 26}

115 **Auditory complications**

116 We defined self-reported hearing loss (yes, no) and tinnitus (yes, no) as our main
117 determinants of interest for impaired HRQoL. Participating country questionnaires contained
118 slightly different worded questions on hearing (Supplement Table S1). The central PCL data
119 center in Mainz (Germany) aggregated data and harmonized variables between participating
120 countries in 2017.¹⁷ Data on tinnitus (yes, no) were unavailable for the German cohort; thus,
121 we excluded German data for analyses involving tinnitus. We coded missing answers for

122 hearing loss (<1%) and tinnitus (5%) as normal hearing and without tinnitus. We assumed
123 that CCS with hearing loss or tinnitus would be more likely to answer the question than not
124 when compared with CCS without auditory complications.

125 **Clinical and socio-demographic information**

126 Based on previous study findings, we collected clinical and socio-demographic factors
127 possibly associated with HRQoL among CCS: sex (female, male); age at survey; migration
128 background (yes, no); education (primary, secondary, tertiary); occupational status
129 (employed, unemployed); living with a partner (yes, no); currently smoking tobacco (yes, no);
130 drinking >1 alcoholic beverage per week (yes, no); body mass index (BMI); cancer diagnosis
131 according to ICC3-3¹⁹; age at diagnosis; history of relapse (yes, no); surgery (yes, no);
132 chemotherapy (yes, no); radiotherapy (yes, no); HSCT (yes, no).^{12, 21, 23, 27} Respondents self-
133 reported age at survey, migration background, education, occupational status, living with a
134 partner, tobacco smoking status, alcohol consumption, and BMI variables.¹⁷ Demographic,
135 cancer-related, and treatment information were extracted from participating institution
136 medical records or corresponding cancer registries.¹⁷

137 **Statistical analysis**

138 We used *t*-tests and fitted multivariable linear regression models to investigate possible
139 associations of hearing loss or tinnitus with HRQoL. First, we examined whether mean scores
140 on SF-36 health domains and PCS and MCS scores differed between CCS with and without
141 auditory complications. We then fitted multivariable linear regression models to investigate
142 whether any possible association of hearing loss or tinnitus with health domains and PCS and
143 MCS scores were explained by clinical or socio-demographic factors. We chose linear

144 regression because HRQoL outcome variables are continuous and binary categorizations of
145 HRQoL measured by SF-36 is without consensus in the literature. To mitigate effects of
146 sample imbalances between countries, we standardized cohorts from CZ, DE, and FR
147 according to age at survey and sex variables. Because of the balanced distribution across all
148 age groups and genders, we used the CH cohort as the reference population to calculate
149 appropriate weights. Based on the conceptual framework of directed acyclic graphs
150 (Supplement Figure S1),²⁸ we adjusted our models for the following co-variables: age at
151 survey (continuous in years); age at cancer diagnosis (continuous in years); type of cancer
152 (categorical according ICCC-3); history of relapse (yes, no); surgery (yes, no); chemotherapy
153 (yes, no); radiotherapy (yes, no); and HSCT (yes, no). We decided to include country of data
154 provider to adjust for country-specific differences in recruitment of study participants and
155 audiological monitoring.^{17, 29, 30} We calculated global *p*-values using the Wald test.

156 Since we hypothesized the burden of auditory complications may be largest when both
157 tinnitus and hearing loss are present,³¹ we performed a sub-analysis to further investigate a
158 potential causal relationship between auditory complications and HRQoL. We coded auditory
159 complications as either 1) no auditory complications; 2) hearing loss only; 3) tinnitus only; or
160 4) hearing loss and tinnitus.

161 We used Stata version 16.1 (StataCorp LP, Austin, Texas) for all analyses.

162 RESULTS

163 Characteristics of study population

164 In total, 6,318 CCS were available for our analysis. Of the 6,318 CCS, most were from DE
165 (n = 4,650; 74%); 822 (13%) from CH; 592 (9%) from CZ; and 254 (4%) from FR (Table 1).
166 Our study population included 3,326 (53%) females and 2,992 (47%) males with median age
167 of 31 (interquartile range [IQR] 28-35 years) at survey, median age 9 (IQR 5-13 years) at
168 cancer diagnosis, and median 23 years (IQR 19-28) since cancer diagnosis. Leukemias (n =
169 2,033; 32%), lymphomas (n = 1,466; 23%), and central nervous system (CNS) tumors (n =
170 892; 14%) were most common cancer diagnoses. CCS received cancer treatment by surgery
171 (2,580; 41%); chemotherapy (5,070; 80%); and radiotherapy (3,092; 49%).

172 Prevalence of auditory complications after childhood cancer

173 Of participating CCS, 7.5% (476/6,318; CI: 6.9-8.2) reported hearing loss. Data on tinnitus
174 was available for the cohorts from CH, CZ, and FR resulting in a combined cohort of 1,668
175 CCS. Of those, 7.6% (127/1,668; CI: 6.4-9.0) reported tinnitus. Among CCS with tinnitus (n=
176 127), 45 (35%) also reported hearing loss. CCS diagnosed with CNS tumors, neuroblastoma,
177 hepatic tumors, malignant bone tumors, soft tissue sarcomas, germ cell tumors, and epithelial
178 neoplasms reported hearing loss more often than CCS diagnosed with leukemia (all $p <$
179 0.001) (Figure 1). CCS of hepatic tumors had the highest prevalence of hearing loss (8/28;
180 28.6%, CI: 13.2-48.7) followed by malignant bone tumors (91/378; 24.1%, CI: 19.8-28.7) and
181 CNS tumors (130/892; 14.6%, CI: 12.3-17.1). Tinnitus prevalence was highest among CCS
182 diagnosed with malignant bone tumors (16/103; 15.5%, CI: 9.1-24.0) and CNS tumors
183 (33/255; 12.9%, CI: 9.1-17.7) (Figure 2).

184 Association of auditory complications with HRQoL

185 CCS with hearing loss had lower HRQoL mean scores than CCS with normal hearing (all
186 differences with $p < 0.001$) (Figure 3A). Looking at SF-36 summary scores, CCS with hearing
187 loss scored 45.3 in overall physical (PCS) and 46.0 in overall mental (MCS) HRQoL. In
188 comparison, CCS with normal hearing had 51.7 for PCS and 50.0 for MCS scores. Among the
189 eight health domains, we observed the largest mean differences between CCS with and
190 without hearing loss in physical functioning (40.6 vs. 48.3), general health (45.1 vs. 50.9), and
191 social functioning (43.0 vs. 48.2).

192 CCS with tinnitus scored lower than CCS without tinnitus in all health domains and PCS
193 (42.7 vs. 52.2) and MCS (43.1 vs. 49.9) summary scores (all differences with $p < 0.001$)
194 (Figure 3B). The largest mean differences between CCS with and without tinnitus were again
195 in physical functioning (40.2 vs. 48.9), general health (41.6 vs. 51.0), and social functioning
196 (39.7 vs. 48.3).

197 In the multivariable linear regression, hearing loss remained associated with lower HRQoL
198 scores after adjusting for socio-demographic and cancer-related factors (Table 2). For PCS,
199 coef. were -4.3 (CI: -7.0 to -1.6) among those with hearing loss and -3.2 (CI: -5.5 to -0.8) for
200 MCS. On average, overall physical or mental HRQoL was reduced by 4.3 or 3.2 points for
201 CCS with hearing loss compared with CCS with normal hearing. The association was
202 strongest for general health, followed by physical functioning, vitality, and social functioning
203 (coef. ranging from -4.6 to -3.8, $p < 0.05$) (Table 2). We observed borderline or no associations
204 of hearing loss in role physical and role emotional.

205 Tinnitus also remained associated with lower HRQoL scores in multivariable linear
206 regression (Table 2). The effects of tinnitus on PCS (coef. -8.2, CI: -11.8 to -4.7) and MCS
207 (coef. -5.9, CI: -8.8 to -3.1) were greater compared with the effects of hearing loss (coef. of -
208 4.3 for PCS and -3.2 for MCS). We found the strongest effect of tinnitus on vitality (coef. -
209 8.4, CI: -11.3 to -5.6), general health (coef. -8.3, CI: -11.4 to -5.3), and social functioning
210 (coef. -7.9, CI: -11.0 to -4.7) (all $p < 0.001$).

211 We found CCS with both tinnitus and hearing loss had lower overall physical and mental
212 HRQoL compared with CCS with hearing loss alone (coef. -14.5 vs. -0.6 for PCS and coef. -
213 5.0 vs. -2.9 for MCS) (Table 3). When compared with tinnitus alone, the effect of hearing loss
214 and additional tinnitus was also larger for overall physical HRQoL (coef. -5.4 vs. -14.5 for
215 PCS), yet similar for overall mental HRQoL (coef. -6.8 vs. -5.0 for MCS).

216 DISCUSSION

217 We found the prevalence of auditory complications varied between cancer diagnoses and
218 the highest prevalence of hearing loss and tinnitus among survivors of CNS and malignant
219 bone tumors. HRQoL was lower among CCS with auditory complications than for those with
220 normal hearing. Hearing loss and tinnitus were strongly associated with physical functioning,
221 vitality, general health, and social functioning. We observed lower HRQoL among CCS with
222 hearing loss and additional tinnitus compared with CCS with hearing loss alone.

223 Strengths and limitations

224 Since our study is the largest cohort of CCS to examine auditory complications and their
225 association with HRQoL, it results in high statistical power and good representativeness
226 because it combined data from population-based and regional well-defined cohorts. Tinnitus
227 is more frequent among CCS compared with the general population,² yet its association with
228 HRQoL among CCS was unknown. We included CCS with all possible cancer treatments, not
229 only those exposed to ototoxic treatments such as platinum-based chemotherapy or CRT,
230 which allowed assessing the burden of auditory complications among the overall population
231 of CCS.³² We applied SF-36—an established and validated instrument widely used in
232 previous studies—to measure HRQoL among CCS, which allows comparing our data with
233 other studies.^{21-23, 27, 33, 34} Data from participating countries were collected centrally and
234 harmonized before merging to avoid data management errors.¹⁷ However, our study results
235 might still be influenced by study design differences of participating countries, leading to
236 potential selection bias. For example, FR did not contact CCS of leukemias, and—similar to
237 DE—sent questionnaires later (≥ 10 years) than CH and CZ (both ≥ 5 years) after cancer

238 diagnosis.¹⁷ Considering the French cohort represents only 4% of the total study population,
239 we assume that selection based on cancer diagnosis did not result in a major bias in our
240 findings. Additionally, time since diagnosis was investigated in two larger population-based
241 studies showing either no or minor effects on HRQoL among CCS.^{23,27} Other limitations
242 relate to the main exposures of interest; hearing loss and tinnitus. Since auditory
243 complications were assessed by questionnaire and dependent on severity, underreporting is
244 possible. For instance, CCS with severe hearing loss possibly received better audiologic care
245 and recall it better than CCS with mild high-frequency hearing loss who are unaware of it.³⁵
246 Additionally, SF-36 does not specifically measure HRQoL related to hearing and may not
247 capture life situations affected by auditory complications.

248 **Comparison with previous studies**

249 Among our study population, 7.5% of CCS reported hearing loss. We observed particularly
250 high prevalence among survivors of hepatoblastoma, CNS tumors, and malignant bone
251 tumors—an expected finding from higher cisplatin or CRT use compared with other cancer
252 treatment regimes.^{5,7} Larger studies on hearing loss prevalence among CCS mostly focused
253 on high-risk populations treated with platinum-based chemotherapy or CRT.⁵⁻⁷ Two
254 population-based studies from Switzerland (Swiss Childhood Cancer Survivor Study;
255 SCCSS) and the United States (Childhood Cancer Survivor Study; CCSS) determined the
256 prevalence of hearing loss among the overall CCS population with questionnaires.^{3,16} The
257 Swiss population in our cohort overlaps with the study population of the SCCSS.^{3,17,36}
258 Therefore, we only compared our data with the CCSS study.¹⁶ Whelan and colleagues found a
259 prevalence of self-reported hearing loss of 5%, which is slightly lower than what we found
260 (7.5%).¹⁶ They included CCS diagnosed in earlier years (1970-1986) compared with our study

261 (1974-2009), which possibly explains the difference. Considering cisplatin was first approved
262 in 1978 for adult cancer treatment, it is possible a higher proportion of CCS in our cohort
263 were treated with ototoxic platinum-based chemotherapy, as Weiss and colleagues also
264 discuss in their SCCSS study.^{3,37}

265 The prevalence of tinnitus was 7.6% among our study population. CCS diagnosed with
266 CNS tumors or malignant bone tumors had a three to four times higher prevalence compared
267 with survivors of leukemias. The higher prevalence is possibly explained by previously
268 identified risk factors for tinnitus among CCS, such as exposure to cisplatin, CRT, and CNS
269 surgeries.⁴ In Meijer and colleagues' systematic review, the prevalence of tinnitus ranged
270 from 3-17%.² They also recently published a population-based study where they estimated the
271 prevalence of tinnitus to be 9.5% among CCS compared with 3.7% for siblings.⁴ Their
272 findings are consistent with our study.

273 Audiological complications were associated with lower HRQoL, particularly with
274 decreased physical functioning, general health, vitality, and social functioning. Physical
275 functioning reflects limitations in physical activities, such as difficulties walking a mile or
276 exercising vigorously due to health problems.²⁰ In a SCCSS study, physical well-being was
277 lower among younger CCS with hearing loss than for CCS with normal hearing.¹² General
278 health reflects current and future health perceptions; for example, how people perceive their
279 health when compared with peers or whether their health deteriorates in the future.²⁰ General
280 health was also heavily impaired among CCS when compared with siblings or the general
281 population in previous studies.^{23,27} The SF-36 assesses vitality with questions such as whether
282 people feel full of energy or tired and worn out.²⁰ Previous studies of the general population
283 showed—depending on severity—patients with tinnitus experience comorbidities, such as

284 sleep disturbance, fatigue, and depression.^{10, 11, 38} Hearing loss possibly leads to feelings of
285 fatigue from long periods of effortful listening.³⁹⁻⁴¹ Impaired social functioning refers to
286 limitations in social activities, such as visiting family and friends, due to physical or
287 emotional health problems.²⁰ CCS with hearing loss reported psychosocial difficulties and
288 communication problems in previous studies examining the impact of hearing loss on
289 HRQoL.¹²⁻¹⁴ Yet, a direct comparison with our study remains difficult because they only
290 included children and adolescents—a study population whose social behavior differs from our
291 adult study population (median age 31 at survey). Data from adult CCS participating in the St.
292 Jude Lifetime Cohort Study showed treatment-related hearing loss associated with reduced
293 social attainment, which possibly relates to decreased social engagement.⁴² However, none of
294 these studies investigated the impact of tinnitus on social behavior and attainment.

295 **Causality between auditory complications and HRQoL**

296 The observed association of lower vitality and social functioning possibly relates to
297 educational and psychosocial problems caused by auditory complications.^{8, 10, 11, 13} Other
298 chronic health problems, such as musculoskeletal or neurological, also affect HRQoL.²⁷ In our
299 study, we could not adjust for other chronic health problems. Since the risk of auditory
300 complications and other chronic health problems increases with more intensive cancer
301 treatment, unobserved late effects in other organ systems could contribute to lower physical
302 and mental HRQoL (Supplement Figure S1).^{4, 5, 7, 43, 44} However, we observed hearing loss
303 with additional tinnitus reduces HRQoL more than hearing loss alone. Since we assumed the
304 burden on daily life is greater when CCS experience both hearing loss and tinnitus, it possibly
305 indicates a causal relationship.³¹ Interestingly, tinnitus alone also had a greater impact on
306 HRQoL than hearing loss alone. Since data are self-reported and tinnitus is probably

307 underreported in our study, further research using objective hearing tests and validated
308 instruments to assess tinnitus are important to understand its impact on CCS.^{30, 45}

309 **Conclusion**

310 Our study showed hearing loss and tinnitus strongly affected HRQoL among CCS—
311 particularly reduced HRQoL among survivors with both, hearing loss and tinnitus. Our
312 findings support current guideline recommendations for timely referrals to audiologists for
313 tinnitus symptoms and optimized treatment of hearing loss and tinnitus since both affect
314 HRQoL.³⁰

315 **AUTHORS CONTRIBUTIONS**

316 SST and KB are the first authors of this paper and both contributed substantially to this
317 work. SST prepared the final data set, wrote the manuscript, performed the data analysis and
318 interpreted the results. KB coordinated the study, contributed to the design, implementation,
319 data collection and harmonization, data preparation, reviewed the manuscript, and commented
320 on data analysis and interpretation. DG and JB were part of the PanCareLIFE coordination
321 team and contributed to the implementation and coordination of the study; they also
322 supervised collection, and harmonization and maintenance of data. TL and AaZD contributed
323 to the study implementation and to data harmonization and they provided their medical
324 expertise for data analysis and interpretation. RK, AW, TK, JK, CB conducted the study in
325 the different countries and contributed to data collection and harmonization. AW was
326 involved in the study design. GC supervised the design, implementation and coordination of
327 the study, and contributed to data collection, harmonization and analysis. GS and CK are
328 senior authors of the study; they were involved in the study design and implementation, in

329 collection, harmonization, and maintenance of data, they supervised analysis and
330 interpretation of data and reviewed the manuscript. All co-authors provided feedback on the
331 manuscript and approved its final version.

332 **ACKNOWLEDGMENTS**

333 We thank all survivors of childhood and adolescent cancers and their families for their
334 participation in our study.

335 PanCareLIFE (Grant no. 602030) is a collaborative project in the 7th Framework Program
336 of the European Union. Project partners are Universitätsmedizin der Johannes Gutenberg-
337 Universität Mainz, Germany (PD Dr P Kaatsch, Dr D Grabow); Boyne Research Institute,
338 Drogheda, Ireland (Dr J Byrne, Ms H Campbell); Pintail Ltd., Dublin, Ireland (Mr C
339 Clissmann, Dr K O'Brien); Academisch Medisch Centrum bij de Universiteit van
340 Amsterdam, the Netherlands (Prof Dr LCM Kremer); Universität zu Lübeck, Germany (Prof
341 T Langer); Stichting VU-VUMC, Amsterdam, the Netherlands (Dr E van Dulmen-den
342 Broeder, Dr MH van den Berg); Erasmus Universitair Medisch Centrum, Rotterdam, the
343 Netherlands; and Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands
344 (Prof Dr MM van den Heuvel-Eibrink); Charité-Universitätsmedizin Berlin, Germany (Prof
345 Dr A Borgmann-Staudt); Westfälische Wilhelms-Universität Münster, Germany (Prof Dr A
346 am Zehnhoff-Dinnesen); Universität Bern, Switzerland (Prof Dr CE Kuehni); Istituto
347 Giannina Gaslini, Genoa, Italy (Dr R Haupt); Fakultni nemocnice Brno, Czech Republic (Dr
348 T Kepak); Centre Hospitalier Universitaire Saint-Étienne, Saint-Étienne, France (Dr C
349 Berger); Kraeftens Bekaempelse, Copenhagen, Denmark (Dr JF Winther); Fakultni
350 nemocnice v Motole, Prague, the Czech Republic (Dr J Kruseova); Universitaetsklinikum

351 Bonn, Bonn, Germany (Dr G Calaminus, K Baust); and University Hospital Essen, Essen,
352 Germany (Prof U Dirksen). The EU Commission takes no responsibility for any use made of
353 the information set out.

354 In Switzerland, we thank the Swiss Childhood Cancer Survivor Study team, the Swiss
355 Paediatric Oncology Group data managers, and the Swiss Childhood Cancer Registry study
356 team. We also thank Marcel Zwahlen for statistical advice. We thank the editorial service of
357 the Institute of Social and Preventive Medicine at the University of Bern for the editorial
358 suggestions.

359 In Czech Republic, at the University Hospital of Brno we thank the team of collaborators
360 from the Children's Hospital in Brno, Masaryk University in Brno, especially Katerina
361 Kepakova, and Brno survivors' association Together Toward a Smile: H Hrstková, V
362 Bajčiová, D Hošnová, Z Kuttnerová, M Blanářová, R Mazúr, I Mikulec, E Bučková, L
363 Červinková, E Bařinová, I Krupková, E Novotná, P Chloupková, Z Wimmerová, L Štrublová,
364 and many other external collaborators and supporters.

365 At the University Hospital of Prague LTFU Care Registry, the authors thank the team of
366 the Prague Childhood Cancer Survivor Study: Aleš Lukš, P Keslová, M Ganevová, V
367 Reichlová, J Bašeová, L Nováková, M Douchová, and M Čepelová.

368 In France, we thank the team of the long-term follow-up study (SALTO): Faure-Contier
369 (Lyon), N Corradini (Lyon), D Plantaz (Grenoble), E Tarral (Grenoble), I Durieu (Lyon), I
370 Guichard (Saint-Étienne), L Casagrande and F Odier (Saint-Étienne), N Gauthier (Lyon), P
371 Métral (Lyon), M Mercier (Lyon), S Billet (Grenoble), C Celette (Grenoble), I Schiff
372 (Grenoble), and A Loubier (Saint-Étienne).

373 In Germany, we thank the team of the Clinic of Phoniatics and Pedaudiology at the
374 University Hospital in Münster and the VIVE group and members of the GCCR: U Creutzig
375 (Hannover), T Langer (Lübeck), J Dobke (Berlin), I Jung (Mainz), I Kerényi (Mainz), C
376 Teske (Bonn), and M Zimmermann (Hannover). In Germany, they also thank the team at
377 GCCR in its role as central data center for PanCareLIFE (Peter Kaatsch, Claudia Spix,
378 Melanie Kaiser, Claudia Bremensdorfer).

379 Our project received funding from the European Union's Seventh Framework Program for
380 research, technological development, and demonstration under Grant no. 602030.

381 In Switzerland, our project received funding from the Swiss Cancer League (Grant no.
382 KLS-3412-02-2014, KLS-3886-02-2016, and HSR-4951-11-2019), the Swiss Cancer
383 Research Foundation (Grant no. KFS-4157-02-2017), the Bernese Cancer League,
384 Kinderkrebshilfe Schweiz, Kinderkrebs Schweiz, and the CANSEARCH Foundation
385 (<https://cansearch.ch/en/>). The work of the SCCR was supported by the Swiss Pediatric
386 Oncology Group, Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und -
387 direktoren, the Swiss Cancer Research, Kinderkrebshilfe Schweiz, Bundesamt für Gesundheit,
388 National Institute for Epidemiology and Cancer Registration, and Celgene.

389 In the Czech Republic, our study received funding from the University Hospital of Brno
390 from the Ministry of Education, Youth and Sports of the Czech Republic, under Grant no.
391 7E13061 and the University Hospital of Prague from the foundation Národ dětem.

392 In France, our study received funding from The Wyeth Foundation, the French National
393 Institute of Cancer (INCa), and the French League against Cancer.

394 In Germany, our study received funding from the German Cancer Aid (Grant No. 110298).

395 Data for this subproject were provided by University of Bern, Switzerland (Prof CE
396 Kuehni); Fakultni nemocnice Brno, Czech Republic (Dr T Kepak); Centre Hospitalier
397 Universitaire Saint-Étienne, France (Dr C Berger); Fakultni nemocnice v Motole, Prague,
398 Czech Republic (Dr J Kruseova); and Universitaetsklinikum Bonn, Bonn, Germany (Dr G
399 Calaminus).

400 Prof Dr NW Paul at the University of Mainz and Prof Dr Lisbeth E Knudsen from the
401 University of Copenhagen provided independent ethics advice.

402 **CONFLICT OF INTEREST STATEMENT**

403 The authors declare that there is no conflict of interest.

404 **DATA AVAILABILITY STATEMENT**

405 The data that support the information of this manuscript were accessed on secured servers
406 of the Institute of Social and Preventive Medicine at the University of Bern. Individual-level
407 sensitive data can only be made available for researchers who fulfil the respective legal
408 requirements. All data requests should be communicated to the corresponding author.

409 **ETHICS STATEMENT**

410 PanCareLIFE is a multinational collaborative research project that has harmonized and
411 combined data from regional and national cohorts across Europe. Data collection and analysis
412 for each cohort was approved by the responsible ethics committee in each participating

413 country. For Germany this is the Ethics Committee of the Medical Association of Westphalia-
414 Lippe and the Medical faculty of the Westphalian Wilhelms University (2012-530-f-S), for
415 Switzerland the Cantonal Ethics Committee of the Canton of Bern (KEK-BE: 166/2014;
416 2021-01462), for the Czech Republic the Ethics Committee for Multi-Centric Clinical Trials
417 of the University Hospital Motol (EK-1723/13) and the Multi-Centric Ethics Committee of
418 the University Hospital Brno (approval date: 2014/10/22), and for France the Personal
419 Protection Committee South East 1 (CPP: 2015-23).

420 REFERENCES

- 421 1. Landier W. Ototoxicity and cancer therapy. *Cancer* 2016;122:1647-58.
- 422 2. Meijer AJM, Clemens E, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM.
423 Tinnitus during and after childhood cancer: A systematic review. *Critical reviews in*
424 *oncology/hematology* 2019;135:1-7.
- 425 3. Weiss A, Sommer G, Kasteler R, Scheinemann K, Grotzer M, Kompis M, Kuehni
426 CE. Long-term auditory complications after childhood cancer: A report from the Swiss
427 Childhood Cancer Survivor Study. *Pediatric blood & cancer* 2017;64:364-73.
- 428 4. Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, van
429 Dulmen-den Broeder E, de Vries ACH, Bresters D, Versluys B, Ronckers CM, Kremer LCM,
430 et al. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a
431 Dutch LATER questionnaire study. *Neuro-oncology advances* 2020;2:vdaa122.
- 432 5. Strebel S, Mader L, Sláma T, Waespe N, Weiss A, Parfitt R, Am Zehnhoff-
433 Dinnesen A, Kompis M, von der Weid NX, Ansari M, Kuehni CE. Severity of hearing loss
434 after platinum chemotherapy in childhood cancer survivors. *Pediatric blood & cancer*
435 2022;69:e29755.
- 436 6. Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ,
437 Loonen JJ, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ,
438 van Grotel M, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of
439 childhood cancer: A DCOG late-effects study. *European journal of cancer (Oxford, England :*
440 *1990)* 2016;69:77-85.
- 441 7. Moke DJ, Luo C, Millstein J, Knight KR, Rassekh SR, Brooks B, Ross CJD, Wright
442 M, Mena V, Rushing T, Esbenshade AJ, Carleton BC, et al. Prevalence and risk factors for

- 443 cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional
444 North American cohort study. *The Lancet. Child & adolescent health* 2021;5:274-83.
- 445 8. Bass JK, Liu W, Banerjee P, Brinkman TM, Mulrooney DA, Gajjar A, Pappo AS,
446 Merchant TE, Armstrong GT, Srivastava D, Robison LL, Hudson MM, et al. Association of
447 Hearing Impairment With Neurocognition in Survivors of Childhood Cancer. *JAMA*
448 *oncology* 2020;6:1363-71.
- 449 9. Orgel E, O'Neil SH, Kayser K, Smith B, Softley TL, Sherman-Bien S, Counts PA,
450 Murphy D, Dhall G, Freyer DR. Effect of Sensorineural Hearing Loss on Neurocognitive
451 Functioning in Pediatric Brain Tumor Survivors. *Pediatric blood & cancer* 2016;63:527-34.
- 452 10. Langguth B. A review of tinnitus symptoms beyond 'ringing in the ears': a call to
453 action. *Current medical research and opinion* 2011;27:1635-43.
- 454 11. Bhatt JM, Bhattacharyya N, Lin HW. Relationships between tinnitus and the
455 prevalence of anxiety and depression. *The Laryngoscope* 2017;127:466-69.
- 456 12. Weiss A, Sommer G, Schindera C, Wengenroth L, Karow A, Diezi M, Michel G,
457 Kuehni CE. Hearing loss and quality of life in survivors of paediatric CNS tumours and other
458 cancers. *Quality of life research : an international journal of quality of life aspects of*
459 *treatment, care and rehabilitation* 2019;28:515-21.
- 460 13. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML. Hearing
461 loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report
462 from the Children's Oncology Group. *Pediatrics* 2007;120:e1229-36.
- 463 14. Rajput K, Edwards L, Brock P, Abiodun A, Simpkin P, Al-Malky G. Ototoxicity-
464 induced hearing loss and quality of life in survivors of paediatric cancer. *International journal*
465 *of pediatric otorhinolaryngology* 2020;138:110401.
- 466 15. van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after
467 treatment for childhood cancer. *The Cochrane database of systematic reviews*
468 2016;2016:Cd010181.
- 469 16. Whelan K, Stratton K, Kawashima T, Leisenring W, Hayashi S, Waterbor J, Blatt
470 J, Sklar CA, Packer R, Mitby P, Robison LL, Mertens AC. Auditory complications in
471 childhood cancer survivors: a report from the childhood cancer survivor study. *Pediatric blood*
472 *& cancer* 2011;57:126-34.
- 473 17. Calaminus G, Baust K, Berger C, Byrne J, Binder H, Casagrande L, Grabow D,
474 Grootenhuis M, Kaatsch P, Kaiser M, Kepak T, Kepáková K, et al. Health-Related Quality of
475 Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE.
476 *JMIR research protocols* 2021;10:e21851.

- 477 18. Byrne J, Grabow D, Campbell H, O'Brien K, Bielack S, Am Zehnhoff-Dinnesen
478 A, Calaminus G, Kremer L, Langer T, van den Heuvel-Eibrink MM, van Dulmen-den
479 Broeder E, Baust K, et al. PanCareLIFE: The scientific basis for a European project to
480 improve long-term care regarding fertility, ototoxicity and health-related quality of life after
481 cancer occurring among children and adolescents. *European journal of cancer* (Oxford,
482 England : 1990) 2018;103:227-37.
- 483 19. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. *International Classification*
484 *of Childhood Cancer*, third edition. *Cancer* 2005;103:1457-67.
- 485 20. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36).
486 I. Conceptual framework and item selection. *Medical care* 1992;30:473-83.
- 487 21. Reulen RC, Winter DL, Lancashire ER, Zeegers MP, Jenney ME, Walters SJ,
488 Jenkinson C, Hawkins MM. Health-status of adult survivors of childhood cancer: a large-
489 scale population-based study from the British Childhood Cancer Survivor Study. *International*
490 *journal of cancer* 2007;121:633-40.
- 491 22. Reulen RC, Zeegers MP, Jenkinson C, Lancashire ER, Winter DL, Jenney ME,
492 Hawkins MM. The use of the SF-36 questionnaire in adult survivors of childhood cancer:
493 evaluation of data quality, score reliability, and scaling assumptions. *Health and quality of life*
494 *outcomes* 2006;4:77.
- 495 23. van Erp LME, Maurice-Stam H, Kremer LCM, Tissing WJE, van der Pal HJH, de
496 Vries ACH, van den Heuvel-Eibrink MM, Versluys BAB, Loonen JJ, Bresters D, Louwerens
497 M, van der Heiden-van der Loo M, et al. Health-related quality of life in Dutch adult
498 survivors of childhood cancer: A nation-wide cohort study. *European journal of cancer*
499 (Oxford, England : 1990) 2021;152:204-14.
- 500 24. Penson A, Walraven I, Bronkhorst E, Maurice-Stam H, Grootenhuis MA, Van der
501 Heiden-van der Loo M, Tissing WJE, Van der Pal HJH, De Vries ACH, Bresters D, Ronckers
502 C, Van den Heuvel MM, et al. The Impact of Cancer-Related Fatigue on HRQOL in
503 Survivors of Childhood Cancer: A DCCSS LATER Study. *Cancers* 2022;14.
- 504 25. Roser K, Mader L, Baenziger J, Sommer G, Kuehni CE, Michel G. Health-related
505 quality of life in Switzerland: normative data for the SF-36v2 questionnaire. *Quality of life*
506 *research : an international journal of quality of life aspects of treatment, care and*
507 *rehabilitation* 2019;28:1963-77.
- 508 26. Ellert U, Bellach BM. [The SF-36 in the Federal Health Survey--description of a
509 current normal sample]. *Gesundheitswesen (Bundesverband der Arzte des Offentlichen*
510 *Gesundheitsdienstes (Germany))* 1999;61 Spec No:S184-90.
- 511 27. Rueegg CS, Gianinazzi ME, Rischewski J, Beck Popovic M, von der Weid NX,
512 Michel G, Kuehni CE. Health-related quality of life in survivors of childhood cancer: the role

- 513 of chronic health problems. *Journal of cancer survivorship : research and practice* 2013;7:511-
514 22.
- 515 28. Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a
516 prerequisite for confounding evaluation: an application to birth defects epidemiology.
517 *American journal of epidemiology* 2002;155:176-84.
- 518 29. Weiss A, Kuonen R, Brockmeier H, Grotzer M, Candreia C, Maire R, Senn P,
519 Stieger C, Rosenfeld J, Veraguth D, Kompis M, Scheinemann K, et al. Audiological
520 monitoring in Swiss childhood cancer patients. *Pediatric blood & cancer* 2018;65.
- 521 30. Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM,
522 Skinner R, Constine LS, Bass JK, Kuehni CE, Langer T, van Dalen EC, Bardi E, et al.
523 Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult
524 cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline
525 Harmonization Group in collaboration with the PanCare Consortium. *The Lancet. Oncology*
526 2019;20:e29-e41.
- 527 31. Joo YH, Han KD, Park KH. Association of Hearing Loss and Tinnitus with
528 Health-Related Quality of Life: The Korea National Health and Nutrition Examination
529 Survey. *PloS one* 2015;10:e0131247.
- 530 32. Strelbel S, Waespe N, Kuehni CE. Hearing loss in childhood cancer survivors. *The*
531 *Lancet. Child & adolescent health* 2021;5:e17.
- 532 33. Nathan PC, Ness KK, Greenberg ML, Hudson M, Wolden S, Davidoff A,
533 Laverdiere C, Mertens A, Whitton J, Robison LL, Zeltzer L, Gurney JG. Health-related
534 quality of life in adult survivors of childhood Wilms tumor or neuroblastoma: A report from
535 the childhood cancer survivor study. *Pediatric blood & cancer* 2007;49:704-15.
- 536 34. Zeltzer LK, Lu Q, Leisenring W, Tsao JC, Recklitis C, Armstrong G, Mertens AC,
537 Robison LL, Ness KK. Psychosocial outcomes and health-related quality of life in adult
538 childhood cancer survivors: a report from the childhood cancer survivor study. *Cancer*
539 *epidemiology, biomarkers & prevention : a publication of the American Association for*
540 *Cancer Research, cosponsored by the American Society of Preventive Oncology*
541 2008;17:435-46.
- 542 35. Weiss A, Sommer G, Kuonen R, Scheinemann K, Grotzer M, Kompis M, Kuehni
543 CE. Validation of questionnaire-reported hearing with medical records: A report from the
544 Swiss Childhood Cancer Survivor Study. *PloS one* 2017;12:e0174479.
- 545 36. Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP, Niggli FK, Egger
546 M, von der Weid NX. Cohort profile: the Swiss childhood cancer survivor study. *International*
547 *journal of epidemiology* 2012;41:1553-64.

- 548 37. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature
549 reviews. Cancer 2007;7:573-84.
- 550 38. Izuhara K, Wada K, Nakamura K, Tamai Y, Tsuji M, Ito Y, Nagata C. Association
551 between tinnitus and sleep disorders in the general Japanese population. The Annals of
552 otology, rhinology, and laryngology 2013;122:701-6.
- 553 39. Bess FH, Hornsby BW. Commentary: listening can be exhausting--fatigue in
554 children and adults with hearing loss. Ear and hearing 2014;35:592-9.
- 555 40. Davis H, Schlundt D, Bonnet K, Camarata S, Bess FH, Hornsby B. Understanding
556 Listening-Related Fatigue: Perspectives of Adults with Hearing Loss. International journal of
557 audiology 2021;60:458-68.
- 558 41. Alhanbali S, Dawes P, Lloyd S, Munro KJ. Self-Reported Listening-Related Effort
559 and Fatigue in Hearing-Impaired Adults. Ear and hearing 2017;38:e39-e48.
- 560 42. Brinkman TM, Bass JK, Li Z, Ness KK, Gajjar A, Pappo AS, Armstrong GT,
561 Merchant TE, Srivastava DK, Robison LL, Hudson MM, Gurney JG. Treatment-induced
562 hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid
563 tumors: Results from the St. Jude Lifetime Cohort Study. Cancer 2015;121:4053-61.
- 564 43. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT,
565 Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, et al.
566 Chronic health conditions in adult survivors of childhood cancer. The New England journal of
567 medicine 2006;355:1572-82.
- 568 44. Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, Chemaitilly W, Ehrhardt
569 MJ, Bass J, Bishop MW, Shelton K, Lu L, et al. The cumulative burden of surviving
570 childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet
571 (London, England) 2017;390:2569-82.
- 572 45. Baguley D, McFerran D, Hall D. Tinnitus. Lancet (London, England)
573 2013;382:1600-7.
- 574

LEGENDS

Table 1	Demographic and clinical characteristics of study population
Table 2	Association of hearing loss and tinnitus with HRQoL from adjusted linear regression
Table 3	Association of combined auditory complications on HRQoL from adjusted linear regression
Figure 1	Prevalence of self-reported hearing loss at the time of the study
Figure 2	Prevalence of self-reported tinnitus at the time of the study
Figure 3	Spider chart showing norm-based mean scores for all eight health domains and the two summary scores of the SF-36 comparing CCS with and without auditory complications
Supplementary Table S1	Questions on auditory complications from the questionnaires of each participating country translated into English
Supplementary Table S2	Norm-based mean scores from SF-36 comparing CCS with hearing loss and normal hearing
Supplementary Table S3	Norm-based mean scores from SF-36 comparing CCS with and without tinnitus
Supplementary Figure S1	Directed acyclic graph (DAG)

non peer-reviewed

TABLE 1 Demographic and clinical characteristics of study population

Demographic characteristics	Total cohort (N=6,318)	
	n	(%)
<i>Sex</i>		
Male	2,992	(47)
Female	3,326	(53)
<i>Age at survey (years)</i>		
25-29.9	2,651	(42)
30-34.9	2,061	(33)
35-39.9	1,074	(17)
40-44	532	(8)
<i>Country of origin</i>		
Germany	4,650	(74)
Switzerland	822	(13)
Czech Republic	592	(9)
France	254	(4)
Clinical characteristics	n	(%)
<i>Age at cancer diagnosis (years)</i>		
0-4.9	1,763	(28)
5-9.9	1,696	(27)
10-18	2,859	(45)
<i>Period of cancer diagnosis</i>		
1974-1984	1,254	(20)
1985-1994	3,488	(55)
1995-2004	1,517	(24)
2005-2009	59	(1)
<i>Time since cancer diagnosis (years)</i>		
5-14.9	592	(9)
15-24.9	3,208	(51)
25-42	2,518	(40)
<i>Cancer diagnosis (ICCC-3)</i>		
I Leukemias	2,033	(32)
II Lymphomas	1,466	(23)
III CNS tumours	892	(14)
IV Neuroblastoma	236	(4)
V Retinoblastoma	130	(2)
VI Renal tumours	390	(6)
VII Hepatic tumours	28	(<1)
VIII Bone tumours	378	(6)
IX Soft tissue sarcomas	396	(6)
X Germ cell tumours	249	(4)
XI Epithelial neoplasms & melanomas	80	(1)
XII Other malignant neoplasms	40	(1)
<i>Subsequent tumour</i>		
Yes	458	(7)
No	5,860	(93)

TABLE 1 Continued.

	n	(%)
<i>Treatments^a</i>		
<i>Surgery</i>		
Unknown	863	(14)
Yes	2,580	(41)
No	2,875	(46)
<i>Chemotherapy</i>		
Unknown	603	(10)
Yes	5,070	(80)
No	645	(10)
<i>Radiotherapy</i>		
Unknown	858	(14)
Yes	3,092	(49)
No	2,368	(37)
<i>HSCT</i>		
Unknown	287	(5)
Yes	151	(2)
No	5,880	(93)

Abbreviations: ICCC-3, International Classification of Childhood Cancer–Third Edition; CNS, central nervous system; HSCT, hematopoietic stem cell transplantation.

^aEach subject could have had more than one treatment modality.

non peer-reviewed

TABLE 2 Association of hearing loss and tinnitus with HRQoL from adjusted linear regression analysis

Health Domains	Adjusted ^a association of hearing loss ^b		Adjusted ^a association of tinnitus ^c	
	Coef. (95%-CI)	<i>P</i> ^d	Coef. (95%-CI)	<i>P</i> ^d
<i>Physical Functioning (PF)</i>	-4.5 (-7.7 to -1.4)	0.005	-7.2 (-11.2 to -3.2)	<0.001
<i>Role Physical (RP)</i>	-2.3 (-4.6 to -0.1)	0.044	-5.9 (-8.8 to -2.9)	<0.001
<i>Role Emotional (RE)</i>	-2.5 (-5.4 to 0.4)	0.088	-3.9 (-7.0 to -0.8)	0.014
<i>Bodily Pain (BP)</i>	-2.6 (-4.4 to -0.8)	0.004	-5.3 (-7.6 to -3.0)	<0.001
<i>Mental Health (MH)</i>	-2.8 (-4.7 to -0.8)	0.005	-4.2 (-6.9 to -1.6)	0.002
<i>Vitality (VT)</i>	-3.9 (-6.0 to -1.8)	<0.001	-8.4 (-11.3 to -5.6)	<0.001
<i>General Health (GH)</i>	-4.6 (-6.9 to -2.3)	<0.001	-8.3 (-11.4 to -5.3)	<0.001
<i>Social Functioning (SF)</i>	-3.8 (-6.3 to -1.3)	0.003	-7.9 (-11.0 to -4.7)	<0.001
Global Summary Scores	Coef. (95%-CI)	<i>P</i> ^d	Coef. (95%-CI)	<i>P</i> ^d
<i>PCS</i>	-4.3 (-7.0 to -1.6)	0.002	-8.2 (-11.8 to -4.7)	<0.001
<i>MCS</i>	-3.2 (-5.5 to -0.8)	0.008	-5.9 (-8.8 to -3.1)	<0.001

Abbreviations: Coef., estimated beta coefficient from multivariable linear regression; PCS, physical component summary; MCS, mental component summary.

^aAdjusted for: age at survey (continuous, in years); age at cancer diagnosis (continuous, in years); type of cancer diagnosis (according ICC3-3); history of relapse (yes/no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); HSCT (yes, no); country of data provider.

^bWe included the total cohort for analysis of the association of hearing loss on HRQoL (N=6,318).

^cWe included the cohorts from CH, CZ, and FR for analysis of the association of tinnitus on HRQoL (N=1,668) but excluded the cohort from Germany (n=4,650) because no data on tinnitus was available for the German cohort.

^dP-value calculated from Wald test.

TABLE 3 Association of combined auditory complications on HRQoL from adjusted linear regression analysis

Health Domains	Adjusted ^a association of combined auditory complications	
	Coef. (95%-CI)	<i>P</i> ^c
<i>Physical Functioning (PF)</i>		0.002
No auditory complications	<i>Reference</i>	
Hearing loss only	-0.1 (-3.3 to 3.1)	
Tinnitus only	-3.3 (-6.6 to 0.1)	
Hearing loss and tinnitus	-15.5 (-24.8 to -6.3)	
<i>Role Physical (RP)</i>		0.002
No auditory complications	<i>Reference</i>	
Hearing loss only	0.1 (-2.5 to 2.7)	
Tinnitus only	-4.5 (-7.5 to -1.4)	
Hearing loss and tinnitus	-8.8 (-15.2 to -2.5)	
<i>Role Emotional (RE)</i>		0.053
No auditory complications	<i>Reference</i>	
Hearing loss only	-2.0 (-6.2 to 2.2)	
Tinnitus only	-4.0 (-7.2 to -0.8)	
Hearing loss and tinnitus	-4.3 (-11.0 to 2.3)	
<i>Bodily Pain (BP)</i>		<0.001
No auditory complications	<i>Reference</i>	
Hearing loss only	-1.1 (-3.5 to 1.2)	
Tinnitus only	-4.4 (-7.0 to -1.7)	
Hearing loss and tinnitus	-7.6 (-11.7 to -3.5)	
<i>Mental Health (MH)</i>		0.007
No auditory complications	<i>Reference</i>	
Hearing loss only	-2.3 (-5.1 to 0.6)	
Tinnitus only	-4.5 (-7.8 to -1.1)	
Hearing loss and tinnitus	-4.3 (-8.3 to -0.3)	
<i>Vitality (VT)</i>		<0.001
No auditory complications	<i>Reference</i>	
Hearing loss only	-3.0 (-6.1 to 0.1)	
Tinnitus only	-8.7 (-12.2 to -5.2)	
Hearing loss and tinnitus	-8.6 (-13.1 to -4.2)	

TABLE 3 Continued.

Health Domains	Coef. (95%-CI)	<i>P</i> ^c
<i>General Health (GH)</i>		<0.001
No auditory complications	<i>Reference</i>	
Hearing loss only	-2.6 (-6.1 to 0.9)	
Tinnitus only	-7.2 (-11.0 to -3.4)	
Hearing loss and tinnitus	-11.4 (-15.8 to -7.0)	
<i>Social Functioning (SF)</i>		<0.001
No auditory complications	<i>Reference</i>	
Hearing loss only	-1.6 (-5.0 to 1.8)	
Tinnitus only	-7.0 (-10.4 to -3.6)	
Hearing loss and tinnitus	-10.0 (-16.2 to -3.9)	
Global Summary Scores	Coef. (95%-CI)	<i>P</i>^c
<i>PCS</i>		<0.001
No auditory complications	<i>Reference</i>	
Hearing loss only	-0.6 (-3.5 to 2.2)	
Tinnitus only	-5.4 (-8.8 to -1.9)	
Hearing loss and tinnitus	-14.5 (-21.9 to -7.1)	
<i>MCS</i>		<0.001
No auditory complications	<i>Reference</i>	
Hearing loss only	-2.9 (-6.2 to 0.5)	
Tinnitus only	-6.8 (-10.1 to -3.5)	
Hearing loss and tinnitus	-5.0 (-10.0 to 0.1)	

Abbreviations: PCS, physical component summary; MCS, mental component summary.

^aAdjusted for: age at survey (continuous, in years); age at cancer diagnosis (continuous, in years); type of cancer diagnosis (according ICCC-3); history of relapse (yes/no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); HSCT (yes, no); country of data provider.

^bWe included the cohorts from CH, CZ, and FR for the analysis (N=1,668) but excluded the cohort from Germany (n=4,650) because no data on tinnitus was available for the German cohort.

^c*P*-value calculated from Wald test.




FIGURE 1 Prevalence of self-reported hearing loss at the time of the study (N=6,318). P -values are calculated from χ^2 -statistics comparing prevalence between survivors of leukemia with survivors of other tumor types.

Abbreviations: CNS, central nervous system.




FIGURE 2 Prevalence of self-reported tinnitus at the time of the study (N=1,668). Data from the cohorts of CH, CZ, and FR are shown. No data on tinnitus was available for the German cohort (n=4,650).

P-values are calculated from chi²-statistics comparing prevalence between survivors of leukemia with survivors of other tumor types.

Abbreviations: CNS, central nervous system.




FIGURE 3 The two spider charts (A, B) show norm-based mean scores for all eight health domains and the two summary scores of the SF-36 comparing [A] CCS with hearing loss and normal hearing (N=6,318) and [B] CCS with tinnitus only, tinnitus and hearing loss, and without tinnitus (N=1,668). We included the cohorts from CH, CZ, and FR for the analysis of the association of tinnitus on HRQoL [B] (N=1,668) but excluded the cohort from Germany (n=4,650) because no data on tinnitus was available for the German cohort

Higher scores indicate better HRQoL. Normal population (shown as dashed line) has an estimated mean score of 50 with a standard deviation of 10 for all HRQoL scores of the SF-36. Raw data of the figure are shown in the supplement (Supplement Table S2, S3).

Abbreviations: PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health; PCS, physical component summary; MCS, mental component summary.